NCT06380205View on ClinicalTrials.gov

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

June 7, 2024

Study Completion Date

June 7, 2024

Conditions
Healthy Participants
Interventions
DRUG

Povorcitinib

Povorcitinib will be administered at protocol defined dose.

DRUG

Levonorgestrel/Ethinyl estradiol

Levonorgestrel/Ethinyl estradiol will be administered at protocol defined dose.

Trial Locations (1)

85283

Celerion Clinical Research Unit, Tempe

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY